- Home
- SSTK vs COLL Comparison
SSTK vs COLL Comparison
Compare SSTK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTK
- COLL
- Stock Information
- Founded
- SSTK 2003
- COLL 2002
- Country
- SSTK United States
- COLL United States
- Employees
- SSTK N/A
- COLL 197
- Industry
- SSTK EDP Services
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- SSTK Technology
- COLL Health Care
- Exchange
- SSTK Nasdaq
- COLL Nasdaq
- Market Cap
- SSTK 1.1B
- COLL 1.1B
- IPO Year
- SSTK 2012
- COLL 2015
- Fundamental
- Price
- SSTK $30.95
- COLL $33.35
- Analyst Decision
- SSTK Buy
- COLL Strong Buy
- Analyst Count
- SSTK 4
- COLL 5
- Target Price
- SSTK $50.33
- COLL $43.80
- AVG Volume (30 Days)
- SSTK 925.2K
- COLL 478.2K
- Earning Date
- SSTK 02-19-2025
- COLL 02-20-2025
- Dividend Yield
- SSTK 3.80%
- COLL N/A
- EPS Growth
- SSTK N/A
- COLL 757.11
- EPS
- SSTK 1.01
- COLL 2.16
- Revenue
- SSTK $902,175,000.00
- COLL $599,245,000.00
- Revenue This Year
- SSTK $9.28
- COLL $13.20
- Revenue Next Year
- SSTK $12.47
- COLL $17.63
- P/E Ratio
- SSTK $30.65
- COLL $15.47
- Revenue Growth
- SSTK 3.09
- COLL 9.62
- 52 Week Low
- SSTK $27.30
- COLL $28.39
- 52 Week High
- SSTK $54.41
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- SSTK 50.04
- COLL 62.31
- Support Level
- SSTK $27.30
- COLL $32.29
- Resistance Level
- SSTK $38.80
- COLL $33.99
- Average True Range (ATR)
- SSTK 2.21
- COLL 1.29
- MACD
- SSTK 0.08
- COLL 0.51
- Stochastic Oscillator
- SSTK 31.74
- COLL 87.40
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.